Cancer Family
Childhood Malignant Neoplasm
CI-CAN-00000132Explore in graph →
Pediatric263 active trials1 approved drugs46 evidence items
- NCIt
- C4005
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000132Explore in graph →
Clinical trials
1,178 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (92)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03938987 | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)(ACIT001/EXC002) | recruiting | Phase 1 / Phase 2 | 63 | University of AlbertaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07222735 | Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas | recruiting | Phase 1 | 42 | St. Jude Children's Research HospitalOTHER |
| 1 |
| Feb 9, 2026 |
| clinicaltrials |
| NCT04902313 | Cultivating Resilience in Oncology Practice(CROP) | completed | Phase 1 | 40 | Linkoeping UniversityOTHER_GOV | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05634369 | A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue(TINKS) | recruiting | Phase 1 / Phase 2 | 50 | Nationwide Children's HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06208657 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | recruiting | Phase 1 / Phase 2 | 90 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 2 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06326463 | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | recruiting | Phase 1 | 18 | St. Jude Children's Research HospitalOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07361107 | Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)(ECHO CRC) | recruiting | Phase 1 | 12 | Northwell HealthOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04049383 | CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL(CAR-20/19-T) | terminated | Phase 1 | 5 | Medical College of WisconsinOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07334431 | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer | recruiting | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT07307053 | Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) | not yet recruiting | Phase 1 / Phase 2 | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT03904862 | Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery | terminated | Phase 1 / Phase 2 | 21 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Oct 30, 2025 | clinicaltrials |
| NCT02879643 | Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy | completed | Phase 1 | 29 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Oct 22, 2025 | clinicaltrials |
| NCT04678336 | CD123 Redirected T Cells for AML in Pediatric Subjects | terminated | Phase 1 | 12 | University of PennsylvaniaOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT07108868 | A Phase I Dose Finding Study of MB-CART2219.1 | recruiting | Phase 1 | 36 | University Hospital TuebingenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT04610736 | TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide | completed | Phase 1 | 49 | Orphelia PharmaINDUSTRY | 5 | Jul 31, 2025 | clinicaltrials |
| NCT06732856 | A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer(NEO-CLAUD) | recruiting | Phase 1 / Phase 2 | 57 | Asan Medical CenterOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT02446964 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia | completed | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | active not recruiting | Phase 1 / Phase 2 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Jun 17, 2025 | clinicaltrials |
| NCT03537599 | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 4 | Sumithira VasuOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06742411 | XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC | recruiting | Phase 1 / Phase 2 | 57 | West China HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06871527 | Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05298995 | GD2-CAR T Cells for Pediatric Brain Tumours | recruiting | Phase 1 | 54 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT02323880 | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | completed | Phase 1 | 59 | Children's Oncology GroupNETWORK | 1 | Jan 14, 2025 | clinicaltrials |
| NCT01130077 | A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas | completed | Phase 1 | 60 | James FelkerOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06420076 | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells(BAH246) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03879512 | Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG | completed | Phase 1 / Phase 2 | 24 | Wuerzburg University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05569512 | Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML | terminated | Phase 1 | 1 | Malika KapadiaOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT05622591 | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML(Pediatric AML) | withdrawn | Phase 1 | 0 | Elucida OncologyINDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06044142 | Curcumin VS Photo-bio-modulation Therapy of Oral Mucositis in Pediatric Patients Undergoing Anti-Cancer Non-invasive Treatment | completed | Phase 1 | 90 | Riyadh Elm UniversityOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | recruiting | Phase 1 / Phase 2 | 68 | University Hospital HeidelbergOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06456892 | Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen | recruiting | Phase 1 / Phase 2 | 82 | Sun Yat-sen UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT02061800 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | unknown | Phase 1 / Phase 2 | 14 | Diane GeorgeOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT00019630 | Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03964259 | Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 | 10 | Virginia Commonwealth UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT01606878 | Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 | 46 | Children's Oncology GroupNETWORK | 2 | Jan 5, 2024 | clinicaltrials |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer | terminated | Phase 1 / Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT00167219 | Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) | completed | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | terminated | Phase 1 / Phase 2 | 2 | Y-mAbs TherapeuticsINDUSTRY | 5 | Oct 6, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT03709914 | PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)(Pediatric_PK) | unknown | Phase 1 | 21 | Nabriva Therapeutics AGINDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT02642965 | Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 38 | Children's Oncology GroupNETWORK | 2 | Sep 8, 2023 | clinicaltrials |
| NCT02536183 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | terminated | Phase 1 | 2 | AeRang KimOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05077423 | A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Y-mAbs TherapeuticsINDUSTRY | 1 | May 30, 2023 | clinicaltrials |
| NCT05487651 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies(ANCHOR2) | unknown | Phase 1 | 36 | Athenex, Inc.INDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT03705507 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia(SeluDex) | terminated | Phase 1 / Phase 2 | 12 | University of BirminghamOTHER | 3 | May 11, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 9, 2026source: clinicaltrials